Drugs / P-BCMA-ALLO1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04960579 | May 2022 → Mar 2029 expected | plasma cell myeloma | Poseida Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-BCMA-ALLO1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04960579 ↗ |
| Modality | Cell therapy | “P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells” NCT04960579 ↗ |
| Route | Intravenous | “Single weight-based IV administration of P-BCMA-ALLO1” NCT04960579 ↗ |